Findings

What do systematic reviews say?

4,721 questions · 19,640 findings · 2,039 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,754 · 19.1%GRADE not reported 1,273 · 6.5%Very low 4,859 · 24.7%Low 5,568 · 28.4%Moderate 3,240 · 16.5%High 946 · 4.8%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings. Peer reviewer training vs standard journal practice or no training

Stakeholders' assessment of review quality (change score) Assessed using either:A) a 5‐point scale, change scores range from −4 to 4 (3 studies);B) a 5‐point scale, expressed by "slope of quality score change"(1 study); orC) the MQAI, from −144 to... · peer reviewers

1 finding from 1 review

Reviewer training for improving grant and journal peer review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Summary of findings: anti‐pseudomonal antibiotics vs placebo

FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 1130 participants
Low

Summary of findings: anti‐pseudomonal antibiotics vs placebo

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1097 participants
Low

Summary of findings: tobramycin for inhalation powder vs tobramycin

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 517 participants
Moderate

Summary of findings: aztreonam lysine for inhalation vs tobramycin

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 268 participants
Moderate

Summary of findings: levofloxacin for inhalation solution vs tobramycin

FEV1 % predicted: relative change from baseline · adults and children aged over 12 with CF and P aeruginosa

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
High

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Change in FVC · adults and children aged over 12 with CF and P aeruginosa

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
High

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Blastocyst‐stage vs cleavage‐stage embryo transfer

Cumulative pregnancy rate (slow freezing) · Patients with subfertility

Blastocyst‐stage may leads to lower cumulative pregnancy rate (slow freezing) compared with cleavage‐stage embryo transfer (low certainty).

1 finding from 1 review

Cleavage‐stage versus blastocyst‐stage embryo transfer in assisted reproductive technology 2022 · Cochrane Headline outcomes only
OR 0.69 [0.48, 0.99]
4 studies · 512 participants
Low

Blastocyst‐stage vs cleavage‐stage embryo transfer

Cumulative pregnancy rate (vitrification) · Patients with subfertility

Blastocyst‐stage probably leads to higher cumulative pregnancy rate (vitrification) compared with cleavage‐stage embryo transfer (moderate certainty).

1 finding from 1 review

Cleavage‐stage versus blastocyst‐stage embryo transfer in assisted reproductive technology 2022 · Cochrane Headline outcomes only
OR 2.44 [1.17, 5.12]
1 study · 120 participants
Moderate

Blastocyst‐stage vs cleavage‐stage embryo transfer

Clinical pregnancy rate · Patients with subfertility

Blastocyst‐stage probably leads to higher clinical pregnancy rate compared with cleavage‐stage embryo transfer (moderate certainty).

1 finding from 1 review

Cleavage‐stage versus blastocyst‐stage embryo transfer in assisted reproductive technology 2022 · Cochrane Headline outcomes only
OR 1.25 [1.12, 1.39]
32 studies · 5821 participants
Moderate

Blastocyst‐stage vs cleavage‐stage embryo transfer

Multiple pregnancy rate · Patients with subfertility

Blastocyst‐stage showed no clear difference in multiple pregnancy rate compared with cleavage‐stage embryo transfer (low certainty).

1 finding from 1 review

Cleavage‐stage versus blastocyst‐stage embryo transfer in assisted reproductive technology 2022 · Cochrane Headline outcomes only
OR 1.12 [0.9, 1.38]
22 studies · 4208 participants
Low

Physical activity vs no physical activity

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Physical activity and exercise training in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 367 participants
Low